Companies › BioAge Labs
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BGE-102 Decreases inflammation | – | Phase 2 | Obesity and Cardiovascular Risk; Diabetic Macular Edema (DME) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07656727 | BGE-102 | Phase 2 | Obesity and Cardiovascular Risk | Cardiovascular | Nov 2026 |
| NCT07812090 | BGE-102 | Phase 2 | Diabetic Macular Edema (DME) | Ophthalmology | Nov 2027 |
Cash and short-term investments of $284m on 2026-09-30; operating cash outflow about $100m a year; runway about 34 months at that burn, to Aug 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Tectonic Therapeutic Cytokinetics Kiora Pharmaceuticals Vantage Biosciences Nyrada
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.